NCT06449352View on ClinicalTrials.gov

Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

September 22, 2025

Study Completion Date

September 22, 2025

Conditions
Normal Tension Glaucoma
Interventions
DRUG

Netarsudil

netarsudil 0.02%

DRUG

Brimonidine

brimonidine 0.1%

Trial Locations (4)

76549

Westlake Eye Specialists - Killeen Office, Killeen

78130

Westlake Eye Specialists - New Braunfels Office, New Braunfels

78640

Westlake Eye Specialists - Kyle Office, Kyle

78746

Westlake Eye Specialists - Austin Office, Austin

All Listed Sponsors
collaborator

Sengi

INDUSTRY

lead

Westlake Eye Specialists

OTHER

NCT06449352 - Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost | Biotech Hunter | Biotech Hunter